A Double-blind, Randomized, Comparative, Multicenter, Exploratory, and Placebo-controlled Phase II Trial of FOLFIRI Plus MSC1936369B or Placebo With a Safety run-in Part as Second-line Treatment of Metastatic K Ras Mutated Colorectal Cancer Subjects
Phase of Trial: Phase I/II
Latest Information Update: 21 Oct 2016
At a glance
- Drugs Pimasertib (Primary) ; Fluorouracil; Folinic acid; Irinotecan
- Indications Colon cancer; Colorectal cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors EMD Serono
- 10 Jun 2017 Biomarkers information updated
- 01 Apr 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 05 Jan 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.